Because most prescription drugs selected for negotiation are highly rebated and discounted—prior to the federal government negotiations—comparisons of MFPs with list prices are somewhat misleading. Many of the ten drugs chosen already had significant rebates, in some cases as high as 68% off of the wholesale acquisition cost.

In this webinar, you'll explore the impact of RSV on U.S. infants, examine key clinical studies on nirsevimab, and review global real-world data on its effectiveness. You'll also learn how to implement immunization strategies to reduce RSV lower respiratory tract infections (LRTI), with practical takeaways for improving coverage and reimbursement decisions.

AMCP recently hosted its third iteration of the IRA workshop series, bringing together health plans, pharmaceutical manufacturers, PBMs, research institutes, and patient advocacy organizations.

View AMCP letter urging Congress to support 12-month continuous eligibility for adults in Medicaid and the Children’s Health Insurance Program (CHIP) by passing the Stabilize Medicaid and CHIP Coverage Act

Meet Adrian Washington, VP of Client Management at a pharmaceutical company and AMCP member for more than 20 years.

Meet Maher Abdel Sattar, FAMCP, MS, PharmD, a volunteer with AMCP for over 15 years and currently an Associate Director of Affairs Operations at a Pharmaceutical Company.

Meet Macy Meng, an AMCP Student Pharmacist Committee Chair (2024-2025) and AMCP member since 2023.